MEREO BIOPHARMA GROUP PLC's ticker is MREO and the CUSIP is 589492107. A total of 62 filers reported holding MEREO BIOPHARMA GROUP PLC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,899,178 | +24.2% | 2,247,425 | +27.1% | 0.00% | – |
| Q2 2023 | $2,334,873 | +8.3% | 1,768,843 | -42.0% | 0.00% | – |
| Q1 2023 | $2,155,310 | -11.4% | 3,048,960 | -6.0% | 0.00% | -100.0% |
| Q4 2022 | $2,432,724 | -13.9% | 3,243,632 | -1.2% | 0.00% | 0.0% |
| Q3 2022 | $2,826,000 | -16.1% | 3,282,087 | +9.1% | 0.00% | 0.0% |
| Q2 2022 | $3,368,000 | -23.3% | 3,007,725 | -23.3% | 0.00% | 0.0% |
| Q1 2022 | $4,393,000 | -31.9% | 3,922,135 | -2.7% | 0.00% | 0.0% |
| Q4 2021 | $6,448,000 | -35.5% | 4,029,514 | -2.5% | 0.00% | -50.0% |
| Q3 2021 | $10,004,000 | +3.4% | 4,134,420 | +35.5% | 0.00% | 0.0% |
| Q2 2021 | $9,674,000 | +11.7% | 3,051,768 | +18.7% | 0.00% | 0.0% |
| Q1 2021 | $8,660,000 | -41.2% | 2,569,958 | -37.6% | 0.00% | -50.0% |
| Q4 2020 | $14,733,000 | +31246.8% | 4,115,455 | +22626.0% | 0.00% | – |
| Q3 2020 | $47,000 | – | 18,109 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 2,048,757 | $6,904,000 | 2.75% |
| Asymmetry Capital Management, L.P. | 1,063,264 | $3,583,000 | 1.85% |
| Endurant Capital Management LP | 1,339,835 | $4,515,000 | 1.18% |
| Altium Capital Management LP | 1,250,000 | $4,213,000 | 1.17% |
| Affinity Asset Advisors, LLC | 900,000 | $3,033,000 | 1.03% |
| DAFNA Capital Management LLC | 1,249,648 | $4,211,000 | 1.00% |
| Boxer Capital, LLC | 6,226,673 | $20,984,000 | 0.71% |
| Delphi Management Partners VIII, L.L.C. | 256,734 | $865,000 | 0.60% |
| Rubric Capital Management LP | 2,914,861 | $9,823,000 | 0.57% |
| Orbimed Advisors | 17,264,763 | $58,183,000 | 0.54% |